Objective: Methods to minimize surgical trauma from mediastinal lymphadenectomy in patients with early-stage lung cancer are still immature. This study aimed to identify predictors of negative pathologic N2, which may be used to select patients for limited mediastinal lymphadenectomy.
Results: Multivariable analysis revealed that tumor size 2 cm, negative pN1, lymphovascular invasion, and lepidic adenocarcinoma were associated with negative mediastinal nodal metastasis. Notably, none of the patients with histology of adenocarcinoma in situ, minimally invasive adenocarcinoma, or lepidic pattern-predominant adenocarcinoma on final pathology had pN2 disease, and the 5-year overall and recurrence free-survival of these patients (99.3% and 99.3%, respectively) was not different from those after limited mediastinal lymphadenectomy (98.7% and 100%, P ¼ .582 and .511, respectively). If these subtypes were classified together as the low-risk group, the concordance rate between frozen section and final pathology diagnosis was 88.9% in the retrospective test cohort.
Conclusions: Tumor histology may predict negative mediastinal metastasis in patients with early-stage lung cancer. Future prospective studies are merited to validate the feasibility of using frozen section to select patients for limited mediastinal lymphadenectomy. (J Thorac Cardiovasc Surg 2018;155:2648-56) Selection of patients with low risk of pN2 by frozen section diagnosis in cStage I NSCLC.
Central Message
Lepidic-predominant histology predicts negative pN2 in clinical stage I non-small cell lung cancer.
Perspective
Lepidic histology in associated with negative pN2 in early-stage non-small cell lung cancer. Intraoperative identification of tumor with lepidic-predominant histology on frozen section may be applied in selecting patients for limited mediastinal lymphadenectomy in the future to minimize surgical trauma.
See Editorial Commentary page 2657.
Systematic mediastinal lymph node dissection is the golden standard of nodal staging in lung cancer surgery, which identifies patients who may benefit from adjuvant chemotherapy. 1 However, in patients without nodal metastasis, prophylactic lymphadenectomy has no benefit on survival. 2, 3 Moreover, mediastinal lymphadenectomy may increase operative time and drainage and may cause damage to neurogenic, vascular, and lymphatic structures within the mediastinum, leading to increased risk of postoperative morbidity such as chyle leaks and recurrent nerve injury. [4] [5] [6] With advances in imaging techniques, a greater incidence of lung cancer is diagnosed at early stages, in which nodal metastasis is less common. 7, 8 The emerging challenge to thoracic surgeons now is how to minimize surgical trauma without compromising the effectiveness of the surgery in these patients. As significant improvements have been made in reducing incisional trauma and preserving lung parenchyma, achievement in minimizing damage from mediastinal lymph node dissection is still in its infancy. 2, 9 Although systematic mediastinal sampling may be as effective as dissection in term of survival, 2 its value in reducing surgical trauma is insignificant. 6 Other selective strategies for limited lymphadenectomy may reduce staging accuracy. 9, 10 The key to a good selective strategy is finding a reliable method that can correctly predict negative mediastinal nodal status. Currently, this method is lacking.
In this retrospective study, we aimed to investigate whether tumor histology can predict mediastinal nodal status in clinical stage I non-small cell lung cancer (NSCLC) and to test the accuracy of frozen section (FS) diagnosis for predicting histologic subtypes, which may be used as a tool to select patients for limited lymphadenectomy in the future.
METHODS Patients
This retrospective study was approved by the institutional review board of Fudan University Shanghai Cancer Hospital. From April 2008 to February 2015, 2598 patients underwent resection for primary NSCLC and systematic mediastinal lymphadenectomy in our center. Preoperative tests including contrast-enhanced chest computed tomography (CT) scan, abdominal CT scan or ultrasonography, brain magnetic resonance imaging or CT scan, and radionuclide bone scan or position emission tomography/CT were performed. Clinical stage was determined according to the eighth edition of the tumor, node, and metastasis classification for lung cancer. 11 After exclusion, 1430 patients with primary clinical stage I NSCLC were eligible for the retrospective evaluation ( Figure 1 ). In addition, as the current study specifically excluded patients who did not have a complete lymphadenectomy, to evaluate the impact of limited mediastinal lymphadenectomy on survival of patients with lepidic pattern-predominant adenocarcinoma (LPA), 82 consecutive patients with a final pathologic diagnosis of LPA who had only limited mediastinal lymphadenectomy from the same time frame of the study, including 31 patients with no dissection and 51 patients with selective sampling, were also included for survival analysis.
Definitions of Systematic and Limited Mediastinal Lymphadenectomy
Systematic mediastinal lymph node dissection is defined as complete removal of at least 3 mediastinal nodal stations. 2, 12 In most cases, mediastinal stations 2R, 4R, 7, and 8 for right-sided tumors and stations (Video 1) 5, 6, 7, and 8 for left-sided tumors were removed as the standard treatment. Station 9 was also removed for tumors located in the lower lobes. All hilar, lobar, and interlobar nodes were dissected as a part of lung resection. In some cases, limited mediastinal lymphadenectomy including no nodal dissection, incomplete mediastinal lymph node sampling, and dissections of no more than 2 mediastinal stations were performed if the tumor was subsolid on CT or had intraoperative FS diagnosis of adenocarcinoma in situ (AIS) or minimally invasive carcinoma (MIA). Lung resections including lobectomy, sublobar resection, and pneumonectomy were performed either via muscle-sparing thoracotomy or video-assisted approaches.
Pathologic Evaluation
After resection, all paraffin-embedded specimens were reviewed by at least 2 experienced pathologists and the final pathologic diagnosis was made based on the 2015 World Health Organization classification of lung tumors. 13 Adenocarcinoma was further subtyped to AIS, MIA, LPA, acinar pattern-predominant adenocarcinoma (APA), papillary 14 The tumor specimen was sliced at the largest diameter immediately after the resection and usually 1 to 2 sections of each specimen were made for FS diagnosis. To test the accuracy of FS in further subtyping adenocarcinoma, 126 cases of adenocarcinoma from the study cohort after January 2012 (n ¼ 754) were randomly selected in a ratio of 1 to 6 using a random number table. Their FS were retrospectively reviewed by 2 pathologists who were blinded to the final pathologic diagnosis, and the histologic subtypes were assigned to the tumors by the same criteria defined previously under a nonintraoperative setting.
Patient Follow-up
For the first 2 years, all patients were followed every 3 months and physical examination, chest CT scan, and abdominal ultrasonography were performed. The follow-up frequency was every 6 months for the third year and once per year for subsequent years. Brain magnetic resonance imaging or CT scan and bone scan were performed every year. Recurrence-free survival (RFS) was defined as the time from the date of the operation until the first recurrence or the last follow-up. Overall survival (OS) was defined as the interval between the date of the operation and the date of death or the last follow-up.
Statistical Analysis
The Pearson c 2 test was used to compare frequencies for categorical variables. Univariable regression was conducted, and the variables that were significant (P < .05) were retained for multivariable logistic regression. To overcome the problem of ''separation,'' a penalized maximum likelihood logistic regression in conventional logistic regression was used. 15 Normality of the continuous variables were examined by Kolmogorov-Smirnov test, and the differences between groups were compared by the Student t test for normally distributed data and by Mann-Whitney U test or Kruskal-Wallis one-way analysis of variance for data that were not normally distributed. The concordance between FS and the final pathology diagnoses was evaluated by Cohen's Kappa 
RESULTS

Patient Characteristics
Clinicopathologic characteristics of patients with or without mediastinal lymph node metastasis are shown in Table 1 . The total upstaging rate was 21.6%, including 106 patients (7.4%) with only N1 metastasis, 71 patients (5.0%) with only N2 metastasis, and 131 patients (9.2%) with both N1 and N2 metastasis. A median of 16 lymph nodes were dissected, and more nodes were removed in the patients with N2 metastasis (19 vs 16 nodes in patients without N2 metastasis, P <.001). There was no difference in age, sex, smoking history, history of malignancy, tumor location, or marginal status between the 2 groups. The average tumor size was 2.3 cm in the N2-negative group and 2.7 cm in the N2-positive group (P <.001). Moreover, pathological subtypes were significantly different between the 2 groups (P <.001).
Predictors of Negative Mediastinal Metastasis in Clinical Stage I NSCLC
As presented in Table 2 , risk factors associated with negative pN2 were identified by logistic regression analysis. Tumor with AIS/MIA/LPA histology (odds ratio [OR], 0.095; 95% confidence interval [CI], 0.013-0.695; P ¼ .020), tumor size 2 cm (OR, 0.558; 95% CI, 0.373-0.835; P ¼ .005), negative N1 metastasis (OR, 0.088; 95% CI, 0.059-0.129; P < .001), and negative lymphovascular invasion (OR, 0.364; 95% CI, 0.222-0.597, P < .001) were factors associated with significantly reduced risk of pN2 as identified by both univariable and multivariable analysis.
Mediastinal Nodal Metastasis in Different Histologic Subtypes of Clinical Stage I NSCLC
The rates of pN2 in different histologic subtypes of clinical stage I NSCLC are shown in Figure 2 . Overall, there were 1143 adenocarcinoma, 221 squamous cell carcinomas, and 67 other histologic types, including 32 adenosquamous carcinoma, 7 carcinoid, 20 large cell neuroendocrine carcinoma or large cell carcinoma with neuroendocrine morphology, 4 sarcomatoid carcinoma, and 5 not otherwise specified NSCLC. Adenocarcinomas were subdivided to 3 groups by their malignant grades 16 : the AIS/MIA/LPA group (low malignant grade), the APA/PPA/IMA group (median malignant grade), and the MPA/SPA group (high malignant grade). For the entire cohort, the pN2 rate increased from 5.4% in tumors 1 cm to 20.3% in tumors between 3.1 and 4 cm. Nevertheless, none of patients with AIS (n ¼ 20), MIA (n ¼ 61), or LPA (n ¼ 139) had mediastinal lymph node metastasis, indicating they may be eligible candidates of limited mediastinal lymphadenectomy. This group of patients also had no N1 metastasis or lymphovascular invasion and a significantly greater proportion of tumor 2 cm than other types of NSCLC (P <.001; Figure E1 ). 
Survival Analysis of Patients With Lepidic Adenocarcinoma
Previously we showed the 5-year RFS and OS in patients with AIS/MIA who had sublobar resection without mediastinal lymphadenectomy were both 100%. 14 In this study, the RFS and OS of an additional cohort of 82 patients with LPA who had only limited mediastinal lymphadenectomy were retrospectively reviewed (the median follow-up duration was 40 months, range 5.2-99.8 months). As shown in Figure 3 , the survival of these patients (5-year OS and RFS: 98.7% and 100%, respectively) was not different from the patients with LPA who had complete mediastinal lymph node dissection in the main study cohort (the median follow-up duration was 36.9 months; range 5.3-99.7 months; 5 year OS and RFS: 99.3% and 99.3%; P ¼ .582 and .511, respectively). Only 2 deaths occurred, and neither was cancer related. The survival of the patients with LPA was significantly better than the survival of other pN0 clinical stage I patients (P <.001, Figure E2 ). Postoperative complications in patients with LPA after systematic and limited mediastinal lymphadenectomy are shown in Table E1 .
Concordance Between FS and Final Pathology Diagnosis in Histologic Subtyping of Adenocarcinoma
Previously, we have shown intraoperative FS as an effective method to identify patients with AIS/MIA for sublobar resection, but invasive adenocarcinoma was not further subtyped by FS.
14 In this study, FS of 126 adenocarcinomas were retrospectively reviewed and the histologic subtypes were diagnosed under a nonintraoperative setting. Subtypes of invasive adenocarcinoma were grouped into LPA, APA/PPA/IMA, and MPA/SPA according to their malignant grades (Table 3) . 16 Discrepancy in diagnosis between the FS and the final pathology were seen in 26 cases and the total concordance rate was 79.4% (k ¼ 0.647). If the patients were further categorized to groups of AIS/MIA/LPA and other adenocarcinomas (Table 4) , the concordance rate reached 88.9% (k ¼ 0.753). Of the 14 nonconcordant cases by this categorization, 7 cases were underestimation of other invasive adenocarcinoma to AIS/MIA/LPA by FS, including 6 cases of APA and 1 case of PPA. All of them had lepidic pattern as their second predominant histologic subtype. None of the patients with FS diagnosis of AIS/MIA/LPA had N2 or N1 metastasis in the test cohort.
DISCUSSION
In this study, we retrospectively reviewed clinicopathologic results of 1430 clinical stage I NSCSC and identified tumor histology of AIS/MIA/LPA as a reliable predictor of negative N2 status. The OS and RFS of patients with lepidic adenocarcinoma who had limited mediastinal lymphadenectomy were not different from those who had complete mediastinal lymphadenectomy. In addition, the accuracy (89.9%) of using FS diagnosis to identify this group of patients from other adenocarcinomas under a nonintraoperative setting was satisfactory (k ¼ 0.753), and none of the patients with FS diagnosis of AIS/MIA/ LPA had N2 metastasis. Therefore, avoidance of complete nodal dissection in these patients as guided by FS diagnosis may be a novel strategy to reduce surgical trauma in early-stage lung cancer, which merits further validation by prospective studies.
One of the main findings of this study is the identification of adenocarcinoma with predominant lepidic histology as a unique group in which systematic mediastinal lymph node dissection may be avoided. Regarding the survival, LPA either with or without complete lymphadenectomy had a 5-year survival rate close to 100%, suggesting limited lymphadenectomy is feasible in these patients. Lepidic adenocarcinoma is characterized by noninvasive tumor growth along intact alveolar wall, 13 and based on the extent of invasion this type of tumor can be further categorized to AIS (pure lepidic growth), MIA (predominant lepidic growth with invasion <5 mm), and LPA (predominant lepidic growth with invasion !5 mm). This group of adenocarcinomas typically presents with ground-glass opacity (GGO) feature on high-resolution CT 17, 18 and behaves less aggressively than other subtype of adenocarcinoma. 16, 17 The postoperative RFS and OS of lepidic adenocarcinoma are close to 100%, 18, 19 and their incidence have been increasing recently possibly due to the spread of CT screening. 7, 8, 17 Consistent with our results, Mimae and colleagues 20 showed a significantly lower lepidic component ratio (10% vs 50%) in patients with nodal metastasis. Yu and colleagues 21 also reported negative nodal involvement in 133 patients with LPA. Although description of tumor appearance on CT in this study is not available, previously Flores and colleagues 8 and Hattori and colleagues 18 showed the nodal metastasis rates in lung cancer with predominant (14) 10 (4) 126 (18) 0.647
The number of patients with pN2 in each category is shown in parentheses. FS, Frozen section; AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma; LPA, lepidic pattern-predominant adenocarcinoma; APA, acinar pattern-predominant adenocarcinoma; PPA, papillary pattern-predominant adenocarcinoma; IMA, invasive mucinous adenocarcinoma; MPA, micropapillary pattern-predominant adenocarcinoma; SPA, solid pattern-predominant adenocarcinoma. The number of patients with pN2 in each category is shown in parentheses. FS, Frozen section; AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma; LPA, lepidic pattern-predominant adenocarcinoma; AD, adenocarcinoma.
GGO appearance were close to zero. However, as precise measurement of GGO lesion on CT is still challenging, its use in assisting clinical decision remains datable. 17, 22 Other noninvasive or less-invasive methods to assess nodal status have been described previously. 2, 6, 8, 10, 23 Direct nodal staging by CT or position emission tomography/CT may understage 10% to 30% of patients. 24, 25 Consistently, 21.6% of patients in this study were upstaged by systematic nodal dissection (7.4% with pN1 and 14.2% with pN2). Random lymph node sampling is associated with $10% lower pN2 rate than dissection, 10 and the number of sampled nodes correlates with survival in early-stage patients. 26, 27 In the randomized ACOSOG-Z0030 trial, although systematic mediastinal lymph node sampling was as effective as dissection in term of survival in the patient with N0 or N1 NSCLC, 2 it still missed 4% of pN2 cases and did not reduce surgical morbidity. 2, 6 Tumor size <1 cm used to be suggested as an indicator of pN0 status. 28, 29 However, in both our study and studies by others pN2 were seen in 2.1% to 5.4% of tumors 1 cm. 30, 31 Moreover, as shown in the results, the difference in average tumor size between N2-positive and N2-negative tumors was only 4 mm. Pathologic tumor size is hardly available on FS and radiographic tumor size is usually inaccurate, especially in patients with lepidic tumors, all suggesting tumor size is not a reliable discriminating factor. 32 Lobe-specific lymphadenectomy is another selective strategy for limited lymphadenectomy, 33 in which regional mediastinal dissection is performed based on tumor location and FS assessment of N1 nodes. However, this strategy may also have reduced upstaging rate (13.8% vs 21.1%) and lower N2 detection rate (9.0% vs 13.1%) than systematic dissection, 10 possibly due to skip N2 metastasis, as seen in this study (5%). None of the aforementioned methods has the staging accuracy equivalent to systematic mediastinal dissection.
The future possibility of using FS to discriminate patients with lepidic adenocarcinoma for limited lymphadenectomy was also tested retrospectively. Previously, we reported intraoperative FS had a high accuracy (96.1%) for the diagnosis of AIS/MIA, and it is an effective way to guide sublobar resection in these patients (decisional errors in only 0.7% of patients).
14 Similar studies examining the strength of FS for histologic subtyping are scarce. Yeh and colleagues 34 retrospectively reviewed 361 resected stage I lung adenocarcinomas 3 cm (including 19 AIS/MIA and 53 LPA). The accuracy, sensitivity, and specificity of FS for the diagnosis of LPA were 90%, 75%, and 93%, respectively. The majority of the diagnostic errors were underestimation of LPA to AIS or MIA. 34 In the current study, the accuracy of FS in differentiating AIS/MIA/LPA from other subtypes of adenocarcinoma was satisfactory (88.9%, k ¼ 0.753) and none of the misdiagnosed cases had mediastinal metastasis. All 7 cases with underestimation of other adenocarcinoma to lepidic-predominant adenocarcinoma by FS had lepidic pattern as their second predominant subtype, whereas none of the tumors with pN2 in the test cohort had lepidic pattern more than 20%. It is unlikely these patients would have been misdiagnosed as AIS/MIA/LPA by FS. Nevertheless, the actual impact of this selective strategy on staging accuracy needs to be examined in future studies.
This single institutional study was retrospective and contains several limitations. First, the accuracy of histologic subtyping of adenocarcinoma on FS was tested outside of the pressures of the intraoperative setting. Although the pathologists were blinded to the final pathology, they might have different diagnoses if they were subject to the pressures and restrictions of clinical impact. Also, the 126 randomly selected cases may not represent the whole population, and the probability of N2 disease may also vary in populations under different screening and follow-up strategies. 7, 35 Second, both the final pathology and FS diagnoses were made by pathologists only from our center. Interobserver/institution discrepancy may exist because of variations in experiences of the pathologists. 34 Moreover, the diagnostic criteria of LPA have been modified in the past few years, and we used the 2015 World Health Organization classification for diagnosis, which may explain the discrepancy between previous reports and the current study. 13 For the use of this strategy at other sites, we recommend as least 2 experienced pathologists for intraoperative diagnosis based on the 2015 World Health Organization criteria. Third, the survivals of patients with or without complete mediastinal lymph node dissection were compared retrospectively and there might be selective bias due to the surgeon's preoperative judgment on each tumor. The median follow-up time of the patients was relatively short, especially for indolent tumors like AIS/MIA/LPA. It is possible that the impact of lymphadenectomy on survival may be revealed after a longer period of follow-up. Lastly, as surgical procedures and conditions of the patients varied between the complete dissection group and the limited lymphadenectomy group, the impact of limited lymphadenectomy on clinical outcomes such as operative time and morbidity may not represent the real differences between the groups (Table E1) . To overcome the aforementioned problems, prospectively designed, multi-institutional randomized trials with the consideration of staging accuracy, morbidity, and long-term survival should be conducted to further validate the proposed strategy of limited lymphadenectomy. Such a trial has been planned and registered in the ClinicalTrials.gov (NCT03216551) by us.
In summary, tumor histology of AIS/MIA/LPA is associated with a very low risk of mediastinal nodal metastasis in patients with clinical stage I NSCLC.
Intraoperative FS diagnosis may be a useful tool to select this group of patients for limited mediastinal lymphadenectomy and reduce surgical trauma. Future prospective studies are merited to validate its clinical benefits in early-stage lung cancer.
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